Table 2 The comparison of treatments for high-risk patients with LCH
| Â | Initial treatment course I | Initial treatment course II | Continuation treatment |
|---|---|---|---|
SCMC-LCH-2018 Group1 | (W1-W6) Pred 40 mg/m2 × 4w, taper 2w VCR 1.5mg/m2 iv dl qw Ara-C 100mg/m2 iv/IH d1-4 q2w(w1,3,5) | (W7-W22) Pred 40 mg/m2 d1-5 q3w VCR 1.5mg/m2 iv dl qw Ara-C 100mg/m2 iv/IH d1-4 q3w 6-MP 50mg/m2/d, po, qn | (W25-W52) Pred 40mg/m2 d1-5 q3w VCR 1.5/m2 iv d1 q3w Ara-C 100mg/m2 iv/H d1-4 q6w x3 times (w25,31.37) 6-MP 50mg/m2/d, po, qn |
CCHG-LCH-2019 | (W1-W6) Pred 40 mg/m2 × 4w, taper 2w VCR 0.05 kg/m2 iv day1 of w1,2,3,4,5,6 | (W7-W30) Pred 40mg/m2 d1-5 q3w VCR 0.05 kg/m2 iv d1 q3w Ara-C 150mg/m2 iv/IH d1-5 q3w 6-MP 50mg/m2/d, po, qn | (W31-W 52) Pred 40mg/m2 d1-5 q3w VCR 0.05 kg/m2 iv d1 q3w 6-MP 50mg/m2/d, po, qn |
Histiocyte Society LCH-III trial | (W1-W6) Pred 40 mg/m2 × 4w, taper 2w VCR 6mg/m2 iv dl qw | (W7-W12) Pred 40 mg/m2/d, d1-3 qw VCR 6mg/m2 iv dl qw | (W13-W52) Pred 40 mg/m2/d d1-5 q3w VCR 6 mg/m2/d iv q3w 6-MP 50 mg/m2/d for 12 months |